Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...

While Eli Lilly stock has surged beyond a $1 trillion market capitalization, Novo Nordisk is having difficulty keeping up, ...

Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the market as Mounjaro for Type 2 diabetes and as Zepbound for weight management ...

The pharmaceutical giant Eli Lilly's stock has been riding the skyrocketing demand for its weight loss injection Zepbound and diabetes treatment Mounjaro.

Eli Lilly will cut prices for its weight loss drug Zepbound, with single-dose vials now available for $299 per month through ...

Separately, companies, including digital health firm Waltz Health and cardiometabolic care provider 9amHealth announced direct-to-employer programs in collaboration with Lilly and its Danish rival ...

In the early November announcement of its agreement with the government, Lilly pledged to reduce the self-pay price of ...

The pharmaceutical giant and Novo Nordisk said they would lower the prices of their popular weight loss drugs to expand ...

A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a ...

Novo Nordisk A/S is undercutting arch-rival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness to compete on price as it tries to claw back a larger share of the US market ...

Novo Nordisk and Eli Lily have struck deals with the federal government. The deals aim to make their blockbuster weight loss and Type 2 diabetes drugs more affordable under the Medicare and Medicaid ...

Indian health-tech startup Healthify is in talks to partner with more weight-loss drugmakers to offer health, nutrition and ...